Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
Genmab
University of Chicago
M.D. Anderson Cancer Center
Eastern Cooperative Oncology Group
Bayer
M.D. Anderson Cancer Center
Yonsei University
Washington University School of Medicine
Mayo Clinic
University of California, Davis
City of Hope Medical Center
University of California, San Diego
UNC Lineberger Comprehensive Cancer Center
Emory University
ImmunityBio, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Novartis
Washington University School of Medicine
Stanford University
University of Cincinnati
Inhibrx Biosciences, Inc
Universität des Saarlandes
Roswell Park Cancer Institute
Astellas Pharma Inc
Nanobiotix
Washington University School of Medicine
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
University of Chicago
Merck Sharp & Dohme LLC
Hokkaido University Hospital
University of Pittsburgh
Asher Biotherapeutics, Inc.
Merck Sharp & Dohme LLC
Exelixis
ALX Oncology Inc.
ALX Oncology Inc.
Rakuten Medical, Inc.
University of Cincinnati
DEKA Biosciences
Compugen Ltd
The Methodist Hospital Research Institute
Dana-Farber Cancer Institute
Latin American Cooperative Oncology Group
Carisma Therapeutics Inc
NextCure, Inc.
National Cancer Institute (NCI)
National University Hospital, Singapore